• Save
Perioperative Management Of Liver Tranplant Patients1
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

Perioperative Management Of Liver Tranplant Patients1

  • 1,008 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
1,008
On Slideshare
1,008
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Perioperative Management of Liver Transplant Patients January 22/ 2010 Dr.Husni Ajaj Tripoli
  • 2. Topic Objectives
    • 1. Overview of indications & selection for liver transplantation.
    • 2. Identification & treatment of complications associated with liver disease in the preoperative period.
    • 3. Identification & treatment of complications following orthotopic liver transplantation.
    • 4. Induction of immunosuppressive pharmacotherapy following transplantation.
    • 5. Diagnosis & treatment of graft rejection.
  • 3. Orthotopic Liver Transplantation
    • 1 st orthotopic liver transplantation 1963.
    • Approximately 5,000 orthotopic liver transplantations annually for 17,000 in need.
  • 4. Indications for Liver Transplantation in Adults: Etiologies of End-Stage Liver Disease
    • 1. Fulminant Hepatic Failure
    • 2. Alcoholic Liver Disease
    • 3. Chronic Hepatitis C
    • 4. Chronic Hepatitis B
    • 5. Non-alcoholic steatohepatitis
    • 6. Autoimmune Hepatitis
    • 7. Primary Biliary Cirrhosis
    • 8. Primary Sclerosing Cholangitis
    • 9. Hepatic tumors
    • 10. Metabolic and genetic disorders
  • 5. Indications for Liver Transplantation in Adults
    • Presence of irreversible liver disease and a life expectancy of less than 12 months with no effective medical or surgical alternatives to transplantation
    • Chronic liver disease that has progressed to the point of significant interference with the patient's ability to work or with his/her quality of life
    • Progression of liver disease that will predictably result in mortality exceeding that of transplantation (85% one-year patient survival and 70% five-year survival)
  • 6. Manifestations of End-Stage Liver Disease
    • Progressive jaundice
    • Intractable ascites
    • Spontaneous bacterial peritonitis
    • Hepatorenal Syndrome
    • Encephalopathy
    • Variceal bleeding
    • Intractable pruritus
    • Chronic fatigue (such as resulting in loss of gainful employment)
    • Bleeding diathesis or coagulopathy
  • 7. Selection Criteria for Organ Allocation
    • United Network for Organ Sharing (UNOS) governing body for organ allocation utilizes MELD score.
    • Model for End Stage Liver Disease (MELD) Score
      • 0.957 x loge (creatinine) + 0.378 x loge (bilirubin mg/dL) + 1.12 x loge (INR) + 0.643 x 10
      • Range from 10 to 40
      • Special considerations, amendments for HCC, renal failure.
  • 8. Preoperative management of complications associated with hepatic failure & decompensated cirrhosis
    • Hepatic Encephalopathy
    • Cerebral Edema
    • Acute Renal Failure
    • Infection & Sepsis
    • Metabolic Derangements
    • Malnutrition
    • Coagulopathy
    • Portal Hypertension
  • 9. Hepatic Encephalopathy
    • Etiology: Attributed to increased serum ammonia levels secondary to metabolism of nitrogenous substances in the gut.
    • Symptoms: Range from euphoria to coma.
    • Treatment: lactulose, decreased intake of nitrogen containing compounds, oral neomycin.
  • 10. Cerebral Edema
    • Etiology: Unknown
    • Swelling of brain results in increased ICP & herniation.
    • Invasive monitoring with goal of ICP < 20 mmHg & CPP > 50 mmHg.
    • Treatment: Anxiolysis, HOB elevation, hyperventilation, avoidance of overhydration, mannitol diuresis, HD if compromised renal function.
  • 11. Acute Renal Failure
    • Etiology: Toxin induced, Derangements in systemic & intrarenal hemodynamics.
    • Treatment: Prevention of hypotension, treatment of infection, avoidance of nephrotoxic agents.
    • Once established, renal failure in this setting is often irreversible. Early utilization of renal replacement therapy is indicated.
  • 12. Infection & Sepsis
    • Etiology: Immunologic derangements including complement deficiency, reduced opsonins, WBC dysfunction.
    • Treatment: Frequent cultures, including ascites. Broad spectrum antibiotics, including anti-fungals.
  • 13. Metabolic Derangements
    • 1. Hypokalemia
      • Increased sympathetic tone promotes cellular uptake of K. Decreased serum K promotes production of ammonia by the kidney.
    • 2. Hyponatremia
    • 3. Hypoglycemia
      • Secondary to decreased hepatic glycogen stores & decreased gluconeogenesis.
  • 14. Coagulopathy
    • Etiology: Compromised synthetic function, deficiency of coagulation factors, platelet dysfunction.
    • Contribute to GI bleeding in conjunction with portal hypertension.
    • Treatment: Prevention with H2 blockers, PPI. Judicious use of Factor VIIa & FFP.
  • 15.  
  • 16.  
  • 17.  
  • 18. Post-operative complications & management of liver transplant patients
    • Right pleural effusion
      • May affect ventilation, necessitating drainage.
    • Hepatic edema secondary to aggressive resuscitation & increased intravascular volume.
      • Goal CVP 6-10. Minimize increased hepatic vein pressures, sinusoidal congestion that impair graft perfusion & exacerbate reperfusion injury.
  • 19. Post-operative complications & management of liver transplant patients
    • Renal failure
      • Elevation of creatinine & BUN observed in nearly all transplant patients secondary to ATN, hepatorenal syndrome. Usually self-limiting. May necessitate therapy with loop diuretics, renal replacement therapy.
  • 20. Post-operative complications & management of liver transplant patients
    • Electrolyte Derangements
      • Recovering graft increases demand for magnesium & phosphorous.
      • Transfusion of citrate rich blood products results in decreased serum magnesium & calcium.
      • Rapid correction of chronic hyponatremia with isotonic solution can have severe neurological consequence. Judicious use of hypotonic solutions with goal of serum Na 125-130 advised.
  • 21. Post-operative complications & management of liver transplant patients
    • Thrombocytopenia
      • Preoperative portal hypertension results in splenomegaly & platelet sequestration. Generally improves as graft recovers. May necessitate replacement if bleeding is encountered or invasive procedures are planned. Splenectomy is rarely indicated.
      • Platelet dysfunction secondary to renal & hepatic failure may be improved acutely with DDAVP.
  • 22. Post-operative complications & management of liver transplant patients
    • Biliary leak
      • RUQ pain, fever, persistent elevation of bilirubin, liver enzymes. Biloma on CT. Treated with endoscopic stent, percutaneous drainage. Possible surgical revision if duct is ischemic.
    • Hepatic artery thrombosis
      • Persistent elevation or increasing liver enzymes, poor graft function. Diagnosed with U/S, CT angiography, MRA. Treated with immediate revascularization.
  • 23. Induction of Immunosuppression
    • Triple therapy
      • Calcineurin inhibitor (tacrolimus, cyclosporine), anti-proliferative agent (mycophenolate), corticosteroid taper.
      • Initiated immediately following transplantation.
      • Levels followed daily in immediate post-operative period & with decreasing frequency once stabilized in desired range.
    • Agents vary according to etiology of liver disease.
      • Thymoglobulin & Hb Ig utilized in hepatitis patients along with entecavir & prograf to limit viral replication & to avoid coritocsteroid usage.
  • 24. Allograft rejection
    • Hyperacute rejection
      • Secondary to preformed Ab to graft antigen. Extremely rare. Necessitates retransplantation.
    • Acute Cellular Rejection
      • 70% of patients 5 to 14 days following transplant.
      • Heralded by fever, jaundice, elevation of liver enzymes.
      • Diagnosed by liver biopsy. Demonstrates endothelialitis & non-suppurative cholangitis.
  • 25.                                                                        
  • 26.
    • Althaus SJ, Perkins JD, Soltes G, Glickerman D. Use of a Wallstent in successful treatment of IVC obstruction following liver transplantation. Transplantation. 1996 Feb 27;61(4):669-72.
    • Kim BW, Won JH, Lee BM, Ko BH, Wang HJ, Kim MW. Intraarterial thrombolytic treatment for hepatic artery thrombosis immediately after living donor liver transplantation. Transplant Proc. 2006 Nov;38(9):3128-31.
    • Cotler, Scott J , MD UptoDate Treatment of acute cellular rejection in liver transplantation
    • Brown , Robert S., MD, MPH , Dove, Lorna M, MD, MPH UptoDate Patient selection for liver transplantation
    • Eric Goldberg, MD , Sanjiv Chopra, MD UptoDate Overview of the treatment of fulminant hepatic failure
    • Bussutil RW, Klintmalm GB, Transplantation of the Liver, WB Saunders Company, Philadelphia. 1996
    • Peter J. Friend; Charles J. Imber Transplantation Immunology. Current Status of Liver Transplantation pp. 29 – 46, MAR 2006
    • http://med.stanford.edu/shs/txp/livertxp